Skip to main content
. 2021 Jun 28;2021(6):CD004135. doi: 10.1002/14651858.CD004135.pub4

Venn 1995.

Study characteristics
Methods Study design: prospective, randomized study
Study dates: not reported
Setting: outpatient, multicenter, national
Country: United Kingdom
Participants Inclusion criteria: men with:
  • Madsen score > 8

  • Urodynamic evidence of BOO

  • Residual urine volumes < 250 mL

  • Predominantly lateral lobe enlargement

  • No evidence of prostate or bladder cancer

  • No previous surgery on the lower urinary tract


Exclusion criteria: not reported
Total number of participants randomized: 96
Group 1: n = 48 Transurethral microwave Hyperthermia
  • Age (years) 70.5

  • Madsen score 12.7

  • AUA score 19.2

  • AUA bothersome score 11

  • Urinary flow rate (mL/s) 11.5

  • Prostatic volume (cm3) 40.4


* no SD or 95% CI reported
Group 2: n = 48 transurethral sham
  • Age (years) 68

  • Madsen score 13

  • AUA score 20.1

  • AUA bothersome score 12.3

  • Urinary flow rate (mL/s) 10.2

  • Prostatic volume (cm3) 40.6


* no SD or 95% CI reported
Interventions Group 1 (n = 48) TUMT
Participants in the treated group underwent 1 hr of microwave hyperthermia, with a maximum urethral temperature of 46 °C or a maximum rectal temperature of 42.5 °C. The machine was designed and constructed in conjunction with Microwave Engineering Designs, Newport, Isle of Wight, UK (434 MHz, maximum power of 50 W). The antenna was a helical coil, loaded in a modified eyeless 22F Foley Simplastic catheter fitted with water cooling
Group 2 (n = 48) Sham
Treated with the same procedure but without the use of heat
Co‐interventions:
After selection for inclusion in the trial a treatment catheter was inserted under antibiotic cover (gentamicin 80 mg)
Outcomes Urologic symptom scores
How measured: AUA scores (percentage of improvement). Madsen score response rate (responders as those with a score < 8)
Time points measured: baseline,3 and 6 months
Time points reported: baseline,3 and 6 months (responder data only at 3 months)
Subgroups: none
Relevant outcomes not reported in this study
  • Quality of life (measured for multivariate analysis but not reported)

  • Retreatment

  • Ejaculatory function

  • Erectile function

  • Major and minor adverse events

  • Acute urinary retention

  • Indwelling urinary catheter

Funding sources Not available
Declarations of interest Not available
Notes Participants were selected from waiting lists for transurethral resection of the prostate (TURP) at St Thomas's Hospital and Worthing Hospital, or by direct referral.
Cross‐over: after 3 months, 47 participants in the treated group and 46 of the controls were assessed. After 6 months, 42 treated participants and 20 control participants were assessed, because 24 participants in the control group had been made aware of the sham treatment and so were not included in the analysis
Protocol: not available
Language of publication: English
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Low risk Comment: The investigators describe a random component in the sequence generation process.
Quote: “patients were then randomly assigned to either a treated or control group by selection of sealed envelopes prepared before the trial.”
Allocation concealment (selection bias) Unclear risk Comment: Participants and investigators enrolling participants could not foresee assignment, although it is not clear if the envelopes were opaque.
Quote: “patients were then randomly assigned to either a treated or control group by selection of sealed envelopes prepared before the trial.”
Blinding of participants and personnel (performance bias)
All outcomes Unclear risk Comment: It is unclear if personnel was blinded (first 3 months).
Quote: “The patients were not aware of the group to which they were assigned.”
Blinding of outcome assessment (detection bias)
Objective outcomes Low risk Comment: These outcomes are unlikely to be affected by blinding.
Quote: “The patients were not aware of the group to which they were assigned.”
Blinding of outcome assessment (detection bias)
Subjective outcomes Low risk Comment: These outcomes are likely to be affected by blinding.
Quote: “The patients were not aware of the group to which they were assigned.”
Incomplete outcome data (attrition bias)
All outcomes Low risk All outcomes: outcome data was available for nearly all participants. After 3 months, 47/48 patients in the treated group and 46/48 of the controls were assessed (6‐month data not included in this review, see “Notes”)
Selective reporting (reporting bias) Unclear risk No protocol available. Insufficient information to permit judgment of ‘Low risk’ or ‘High risk’.
Other bias Low risk No other sources of bias were identified